A Public Resource Compiled by the

China: Therapeutic / Stem Cell

Print Friendly, PDF & Email
China Flag

Lightly Regulated

Gene therapy is permitted and clinical trials are ongoing.

Gene therapy is allowed and clinical trials only require approval by an ethics committee of a hospital. Approval from national regulatory agencies is not required. Research ethics committees are responsible for ensuring compliance by performing ethical review of their institutions’ biomedical research activities involving human research participants. However, there is uncertainty about whether these regulations are subject to the force of law and penalties and enforcement mechanisms are unclear.

In 2018, a Chinese scientist altered the DNA of human embryos that were carried to term. The announcement sparked an international controversy, and as a result, the Chinese government says it will impose stricter human gene editing regulations

In 2019, a new draft of civil code was submitted by the National Health Commission, which, if approved, would bring medical and scientific germline research under civil legislation. The draft states that human clinical research, including gene editing, must get approval from China’s Ministry of Health (instead of only requiring approval from a hospital’s ethics committee). In addition, scientific and medical studies pertaining to human genes or embryos must “follow the relevant regulations and cannot harm people’s health, breach moral or ethical standards, or violate public interests”. The draft mentions fines and blacklists, but enforcement mechanisms are unclear. The civil code is expected to be adopted in March 2020. The regulations will not apply to preclinical research.

Medical research is regulated by the National Health and Family Planning Commission (NHFPC), formerly known as the Ministry of Health and the National Medical Products Administration (NMPA), formerly known as the China Food and Drug Administration (CFDA). The NMPA is the regulatory authority responsible for clinical trial oversight, approval, and inspections for drugs to be registered. However, national agencies tend only to give general guidance that is then interpreted by local organizations and committees, instead of developing and enforcing strict laws and regulations.

In 2017, the NMPA loosened their regulations for clinical trial approval. The Center for Drug Evaluation, a group within the NMPA, is responsible for processing new drug applications. Currently, if an institution in China wants to conduct clinical trials, it needs to be certified by health authorities. Under the new proposal, however, new sites would only need to register with the NMPA. In addition, the changes give the NMPA 60 working days to either reject or question a clinical trial application. Otherwise, the application is automatically considered approved.


  • Cancer: There have been at least 11 clinical trials at various hospitals, beginning in 2015, to test CRISPR gene therapies for cancer treatment (including esophageal, nasal and head and neck) treatments in humans. Anhui Kedgene Biotechnology, a Chinese startup, is involved in most of the trials.
  • Lung cancer: The first clinical trial of CRISPR. In 2016, researchers at the West China Hospital edited immune cells to treat lung cancer tumors.
  • Head and neck cancer: The first gene therapy ever approved. Gendicine, developed by SiBiono GeneTech Co., was approved for the treatment of head and neck cancer, after a 2003 clinical trial.
  • Melanoma: A gene therapy was approved in 2005 to treat melanoma in patients with recurring skin lesions.
  • CAR-T therapies: Over 150 CAR T-cell therapy studies have been conducted. CAR T-cell therapies collect and use patients’ own immune cells to treat their cancer. One therapy, made by Innovative Cellular Therapeutics Co., is commercially available and clinical trials are underway for another CAR-T therapy to treat certain types of lymphoma.
  • Relapsed cancer: In 2018, Chinese firm Nanjing Legend Biotech tested a CAR T-cell therapy treatment on relapsed multiple myeloma with promising results.
  • HPV: In 2017, researchers at the First Affiliated Hospital of Sun Yat-Sen University targeted genes of the HPV virus to help patients avoid cervical cancer. This was the first trial to use CRISPR to edit cells while they are in the human body.
  • HIV: In 2019, researchers completed the first published use of CRISPR to treat a disease in an adult. The treatment helped give the patient HIV resistance, but did not reach the level of a cure.

Regulatory Timeline

2020: Expected adoption of new civil code in China, which includes personal protections for human genes and stricter regulations for human gene editing.

2019: New civil code draft submitted that states studies involving human genes and embryos must follow the relevant regulations and cannot harm people’s health, breach moral or ethical standards or violate public interests.

2019: He Jiankui, who altered the DNA of human embryos that were carried to term, is censured by the Guangdong health ministry and fired from Southern University of Science and Technology.

2018: State Administration of Market Regulations (SAMR) established, which consolidates three separate ministries, the General Administration of Quality Supervision, Inspection and Quarantine (AQSIQ) and the China Food and Drug Administration (CFDA).

2018: China’s National Health Commission orders an investigation into the work of He Jiankui.

2018: Chinese government orders temporary halt to human gene editing research in response to He Jiankui editing embryos that were carried to term.

2018: He Jiankui offers details about his work using CRISPR to edit human embryos at a gene-editing summit in Hong Kong and is roundly criticized.

2017: China first to use CRISPR on viable human embryos.

2016: National Health and Family Planning Commission issues Measures for the Ethical Review of Biomedical Research Involving Humans, which clarify the responsibilities of medical ethics committees and specify the basic scope of informed consent.

2015: Chinese researchers first to edit genes using CRISPR in a human embryo. A gene associated with a fatal blood disorder was modified, but the embryos were not implanted. The editing was not successful in most embryos in the experiment.

2008: Medical Ethics Expert Committee in the Ministry of Health created and Guidelines for Hospital Management Evaluation released.

2007: Ministry of Health releases Measures for the Ethical Review of Biomedical Research Involving Humans (For Trial Implementation).

2003: Chinese State Food and Drug Administration (CFDA; now called the National Medical Products Administration) publishes “Guidance for Human Gene Therapy Research and Its Products”, which outlines requirements for applications of gene therapy clinical study. The document also outlines requirements for quality controls and product efficacy and safety tests.

2003: State Food and Drug Administration (SFDA) issues the revised Norms on Quality Management of Drug Clinical Trials, requiring all medical institutions conducting clinical trials to be certified and establishing independent research ethics committees filed with the SFDA to “safeguard the rights and interests of all applicants for participation and participants in clinical trials”.

2003: Ministry of Health and the Ministry of Science and Technology jointly develop the Ethical Principles of Research of Human Embryonic Stem Cells.

2001: Ministry of Health releases the Administrative Measures for Assisted Human Reproduction.

1999: Guiding Principles for Human Gene Therapy Clinical Trials finalized.

1999: SFDA issues the Norms on Quality Management of Drug Clinical Trials.

1997: Minister of Health orders establishment of research ethics committees at medical research institutions.

1993: Chinese Ministry of Public Health releases “An Outline of Quality Controls for Clinical Studies of Human Somatic and Gene Therapy.”

1988: Chinese Society of Medical Ethics of the Chinese Medical Association founded.

NGO Reaction

The alteration of the DNA of human embryos that were carried to term has drawn international condemnation from scientists, researchers and organizations. Chinese researchers joined an international call in 2019 for a global moratorium on all clinical uses of germline editing. Worldwide, the scandal has initiated a re-evaluation of human gene editing laws.

Additional Resources

Click on a country (eg. Brazil, US) or region (eg. European Union) below to find which human / health products and processes are approved or in development and their regulatory status.

European Union


New Zealand

United States




United Kingdom












Southeast Asia

Central America




Human / Health Gene Editing Index
Compare Regulatory Restrictions Country-to-Country

Gene editing regulations worldwide are evolving. The Gene Editing Index ratings below represent the current status of gene editing regulations and will be updated as new regulations are passed.

Colors and ratings guide

Regulation StatusRating
Determined: No Unique Regulations*10
Lightly Regulated8
Proposed: No Unique Regulations†6
Ongoing Research, Regulations In Development5
Highly Regulated4
Mostly Prohibited2
Limited Research, No Clear Regulations1
Lightly Regulated: Gene and stem cell therapies regulated with minimal restrictions and requirements.
*Determined: No Unique Regulations: Gene and stem cell therapies regulated as phamaceuticals with no additional restrictions.

†Proposed: No Unique Regulations: Decrees under consideration for gene and stem cell therapies that would not require unique regulations beyond current restrictions on pharmaceuticals.

Gene editing of adult human cells, including gene therapy and stem cell therapy, that is used to treat and cure disease. Recent breakthroughs include CAR T-cell therapy, which uses patients’ own immune cells to treat their cancer.
Gene editing of the human embryo or germline that results in genetic changes that are passed down to the next generation. This type of gene editing is the most controversial because changes are inherited and because it could theoretically be used to create “designer babies”. A Chinese scientist announced in 2018 that he had successfully edited twins that were brought to term. International backlash from the announcement has resulted in China and other countries working to clarify regulations on germline gene editing.

Rating by Country / Region
Click each column header and arrow to sort the countries / regions

Swipe right/left if all columns aren't visible

Country / RegionTherapeuticGermlineHuman Rating
New Zealand402
Central America111
Share via

Gene editing is a set of techniques that can be used to precisely modify the DNA of almost any organism. It is being used for applications in human health, gene drives and agriculture. There are numerous gene-editing tools besides CRISPR-Cas 9, which gets most of the attention because it is a comparatively easy tool to use.

Gene editing does not usually involve transgenics – moving ‘foreign’ genes between species. It also refers to a specific technique in contrast to the general term GMO, which is scientifically ambiguous, as genetic modification is a process not a product. Most gene editing involves creating new products by deleting very small segments of DNA (sometimes in agriculture called Site-Directed Nuclease 1 or SDN-1 techniques), which can silence a gene or change a gene’s activity. Countries are evaluating whether or not to regulate this type of gene editing, since it is so similar to natural mutations. The GLP’s Gene Editing Index ratings reflect the regulatory status of SDN-1 techniques, which are the most liberally regulated and will generate most products in the near term.

To develop different products, gene editing can change larger segments of DNA or add DNA from other species (a form of transgenics sometimes in agriculture called SDN-2 or SDN-3 techniques). While many countries are not regulating or lightly regulating SDN-1 techniques, most are moving toward tightly regulating or even restricting SDN-2 and SDN-3.

For more background on the various gene editing SDN techniques, read background articles here and here.